| Literature DB >> 33115446 |
Kirsi Kemp1,2, Janne Alakare3,4, Veli-Pekka Harjola3,4, Timo Strandberg5,6, Jukka Tolonen3,4, Lasse Lehtonen7, Maaret Castrén3,4.
Abstract
BACKGROUND: The aim of the emergency department (ED) triage is to recognize critically ill patients and to allocate resources. No strong evidence for accuracy of the current triage instruments, especially for the older adults, exists. We evaluated the National Early Warning Score 2 (NEWS2) and a 3-level triage assessment as risk predictors for frail older adults visiting the ED.Entities:
Keywords: Emergency department; Frailty; Older adults; Triage
Mesh:
Year: 2020 PMID: 33115446 PMCID: PMC7594283 DOI: 10.1186/s12873-020-00379-y
Source DB: PubMed Journal: BMC Emerg Med ISSN: 1471-227X
Fig. 1PICO statement for ED outcome prediction for the frail older adults
Fig. 2Patient selection flowchart
Fig. 3Mortality prediction with the NEWS2 score (left) and the 3-level triage instrument (right)
Fig. 4HDU admission prediction with the NEWS2 score (left) and a 3-level triage instrument (right)
Predictive values of triage score and NEWS2 for ED LOS
| Mean Difference (h) | Std. Error | Sig. | 95% CI | |||
|---|---|---|---|---|---|---|
| Lower | Upper | |||||
| Red | Yellow | −3.64* | 0.852 | < 0.001 | −5.63 | −1.64 |
| Red | Green | −4.02* | 0.800 | < 0.001 | −5.90 | −2.14 |
| Yellow | Green | −0.380 | 0.388 | < 0.001 | −1.29 | 0.53 |
| Low | Moderate | 0.07 | 0.564 | 0.993 | −1.26 | 1.39 |
| Low | High | 1.19 | 0.549 | 0.077 | −0.10 | 2.48 |
| Moderate | High | 1.13 | 0.748 | 0.289 | −0.63 | 2.88 |
Our 3 level triage tool (abbreviated and translated from original Finnish version)
STROBE Statement—Checklist of items that should be included in reports of
| Item No | Recommendation | Observed | |
|---|---|---|---|
| 1 | ( | Yes | |
| ( | Yes | ||
| Background/ rationale | 2 | Explain the scientific background and rationale for the investigation being reported | Yes |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | Yes |
| Study design | 4 | Present key elements of study design early in the paper | Yes |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | Yes |
| Participants | 6 | ( | Yes |
| ( | Yes | ||
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | Yes (where applicable) |
| Data sources/ measurement | 8a | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | Yes (where applicable) |
| Bias | 9 | Describe any efforts to address potential sources of bias | Yes |
| Study size | 10 | Explain how the study size was arrived at | Yes |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | Yes |
| Statistical methods | 12 | ( | Yes |
| ( | Yes | ||
| ( | N/A | ||
| ( | N/A | ||
| ( | N/A | ||
| Participants | 13a | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | Yes |
| (b) Give reasons for non-participation at each stage | Yes | ||
| (c) Consider use of a flow diagram | Yes | ||
| Descriptive data | 14a | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | Yes |
| (b) Indicate number of participants with missing data for each variable of interest | N/A | ||
| (c) Summarise follow-up time (eg, average and total amount) | Yes | ||
| Outcome data | 15a | Report numbers of outcome events or summary measures over time | Yes |
| Main results | 16 | ( | Yes |
| ( | Yes | ||
| ( | N/A | ||
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | Yes |
| Key results | 18 | Summarise key results with reference to study objectives | Yes |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | Yes |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | Yes |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | Yes |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | Yes |
aGive information separately for exposed and unexposed groups
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org